α‐Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients
Movement Disorders · 2025-03 · 40 (3) · 550-555
DOI: 10.1002/mds.30094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 23.12.2024. Verfasst von Lorena de Mena und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Parkinson's and Other Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, DNA Methylation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Miguel Servet.
Abstract (Originalsprache)
Background α‐Synuclein ( SNCA ) gene hypomethylation was reported in idiopathic Parkinson's disease (iPD). Based on a high clinical resemblance between iPD and leucine‐rich repeat kinase 2 (LRRK2)‐driven Parkinson's disease (L2PD), we investigated the epigenetic status of SNCA in an extensive LRRK2 clinical cohort from Spain.
Methods
We assessed the methylation levels of 23 CpG sites in the SNCA promoter region using peripheral blood DNA from L2PD patients (n = 151), LRRK2 nonmanifesting carriers (n = 55), iPD patients (n = 115), and healthy control subjects (n = 154) (total: N = 475).
Results
Compared with control subjects, we found significant SNCA hypomethylation in 11 of 23 CpGs in L2PD (48%), whereas 22 CpGs (96%) were hypomethylated in iPD. In line with a healthy status, asymptomatic mutation carriers had similar SNCA methylation profiles to control subjects.
Conclusions
This study shows for the first time that SNCA hypomethylation occurs in patients with L2PD. Further studies addressing SNCA methylation status in additional worldwide LRRK2 cohorts are warranted. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Parkinson's and Other Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
- Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
- Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CB06/05/0018-ISCIII, Barcelona, Spain.
ORCID-Profile: Eduardo Tolosa, Rubén Fernández-Santiago
Förderung
- Instituto de Salud Carlos III (ISCIII) co-funded by the European Union
- Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
- Miguel Servet
- Instituto de Salud Carlos III
Zitieren
APA
de Mena, L., Parés, G., Garrido, A., Pilco-Janeta, D. F., Fernández, M., Pérez, J., Tolosa, E., Cámara, A., Valldeoriola, F., Ezquerra, M., Martí, M. J., Fernández-Santiago, R., & Barcelona LRRK2 Study Group (2025). α‐Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients. Movement Disorders, 40(3), 550-555. https://doi.org/10.1002/mds.30094
Vancouver
de Mena L, Parés G, Garrido A, Pilco-Janeta DF, Fernández M, Pérez J, et al. α‐Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients. Movement Disorders. 2025;40(3):550-555. doi:10.1002/mds.30094
BibTeX
@article{deMena2025,
author = {de Mena, Lorena and Parés, Guillem and Garrido, Alicia and Pilco-Janeta, Daniel F and Fernández, Manel and Pérez, Jesica and Tolosa, Eduardo and Cámara, Ana and Valldeoriola, Francesc and Ezquerra, Mario and Martí, María-José and Fernández-Santiago, Rubén and Barcelona LRRK2 Study Group, Barcelona LRRK2 Study Group},
title = {α‐Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients},
journal = {Movement Disorders},
year = {2025},
volume = {40},
number = {3},
pages = {550--555},
doi = {10.1002/mds.30094}
}
EUVIMED